US 2026/0285802 A1 · MODULATORS OF SORTILIN ACTIVITY

Abstract

The present intervention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical compositions comprising the compounds of the invention, and to their use in the treatment or prevention of medical conditions in which modulation of sortilin is beneficial.

Claims15

Dependent claims

A compound of formula (I):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof;
wherein
R1 is
R2 is H or —CH3;
R3 is selected from the group consisting of C6-C10 aryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents independently selected from —OH, halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 hydroxyalkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 hydroxyalkoxy, acetyl, cyano, C6-C10 aryl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocycloalkyl, —O—(C6-C10 aryl), and —O—CH2—(C6-C10 aryl);
R4 is H or —CH3;
and
n is 0 or 1.

5 more elements

The compound according to any preceding claim, wherein the optional substituents for R3 are independently selected from the group consisting of halo, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, phenyl, 6-membered heterocycloalkyl, —O-phenyl, and —O—CH2-phenyl, preferably halo, cyano, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, phenyl, morpholinyl, —O-phenyl, and —O—CH2-phenyl, more preferably halo, cyano, C1-C2 alkyl, C1-C2 alkoxy, C1-C2 haloalkyl, phenyl, morpholinyl, —O-phenyl, and —O—CH2-phenyl.

The compound according to any preceding claim, wherein R3 is selected from the group consisting of:

preferably R3 is selected from the group consisting of:

The compound according to any preceding claim, wherein the compound is:

(S)-2-anilino-5,5-dimethylhexanoic acid;
(S)-5,5-dimethyl-2-(2-pyridylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(4-pyridylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(2-pyrazinylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(2-pyrimidinylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(5-pyrimidinylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(4-pyrimidinylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(4-quinazolinylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(1,3,5-triaza-4-naphthylamino)hexanoic acid;
(S)-2-[5-(benzyloxy)-2-pyrimidinylamino]-5,5-dimethylhexanoic acid(S)
(S)-2-(5-methoxy-2-pyrimidinylamino)-5,5-dimethylhexanoic acid(S)
(S)-2-(4-methoxy-2-pyrimidinylamino)-5,5-dimethylhexanoic acid(S)
(S)-5,5-dimethyl-2-(4-morpholino-2-pyrimidinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(2-quinoxalinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(5-methyl-2-pyrazinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(3-methyl-2-pyrazinylamino)hexanoic acid(S)
(S)-2-(2-methoxy-4-pyrimidinylamino)-5,5-dimethylhexanoic acid(S)
(S)-2-(6-methoxy-4-pyrimidinylamino)-5,5-dimethylhexanoic acid(S)
(S)-5,5-dimethyl-2-(2-methyl-4-pyrimidinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(6-methyl-4-pyrimidinylamino)hexanoic acid(S)
(S)-2-(2,6-dimethyl-4-pyrimidinylamino)-5,5-dimethylhexanoic acid
(S)-5,5-dimethyl-2-(8-methyl-4-quinazolinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(6-methyl-2-pyrazinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(6-phenoxy-2-pyrazinylamino)hexanoic acid(S)
(S)-2-(4-isoquinolylamino)-5,5-dimethylhexanoic acid(S)
(S)-2-(m-chlorophenylamino)-5,5-dimethylhexanoic acid(S)
(S)-5,5-dimethyl-2-(3-pyridylamino)hexanoic acid
(S)-[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-isoquinolylamine
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-3-quinolylamine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-2-quinolylamine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-1-naphthylamine;
N-phenyl[4-methyl-1-(2H-tetraazol-5-yl)pentyl]amine;
N-2-pyridyl[4-methyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl]-1-naphthylamine;
N-phenyl[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-2-quinolylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-2-pyrazinylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-3-isoquinolylamine;
N-phenyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]-3-quinolylamine;
N-2-pyrimidinyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-4-isoquinolylamine;
N-2-pyrimidinyl[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]-4-isoquinolylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-5-pyrimidinylamine;
N-5-pyrimidinyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
N-2-pyrazinyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl](1-methyl-1H-1,7-diazainden-5-yl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](1-methyl-1H-1,7-diazainden-5-yl)amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]-2-quinolylamine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl]-3-quinolylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-3-quinolylamine;
N-2-pyrimidinyl[4-methyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl]-2-quinolylamine;
N-3-pyridyl[4-methyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]-3-isoquinolylamine;
N-2-pyridyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
N-3-pyridyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-3-pyridylamine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl]-4-isoquinolylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-2-pyrimidinylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-2-pyridylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]aniline;
N-2-pyridyl[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
N-3-pyridyl[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](6-fluoro-4-quinazolinyl)amine;
[(R)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](6-fluoro-4-quinazolinyl)amine;
[(S)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](6-fluoro-4-quinazolinyl)amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]-4-quinazolinylamine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](6-methoxy-4-quinazolinyl)amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl](6-methoxy-4-quinazolinyl)amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl](6-methyl-4-quinazolinyl)amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl](6-fluoro-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](7-fluoro-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](6-methyl-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](7-methyl-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](7-methoxy-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl][6-(trifluoromethyl)-4-quinazolinyl]amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl][7-(trifluoromethyl)-4-quinazolinyl]amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-1,3,7-triaza-4-naphthylamine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](2-methyl-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](7-bromo-4-quinazolinyl)amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl](7-methoxy-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](2-phenyl-4-quinazolinyl)amine;
[(S)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-isoquinolylamine;
[(R)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-isoquinolylamine;
[(R)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-2-quinolylamine;
[(S)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-2-quinolylamine;
[(S)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-quinazolinylamine;
[(R)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-quinazolinylamine;
N-3-pyridyl[(S)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
N-3-pyridyl[(R)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl]-4-quinazolinylamine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-quinazolinylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-4-quinazolinylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-4-pyridylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-4-pyrimidinylamine;
4-[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentylamino]-7-quinazolinecarbonitrile;
4-[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentylamino]-6-quinazolinecarbonitrile;
(S)-5,5-dimethyl-2-(o-phenoxyphenylamino)hexanoic acid;
(S)-2-anilino-4,4-dimethylvaleric acid;
(S)-2-anilino-2,5,5-trimethylhexanoic acid;
(S)-5,5-dimethyl-2-(4-phenyl-2-pyrimidinylamino)hexanoic acid;
(S)-2-[6-(benzyloxy)-2-pyrazinylamino]-5,5-dimethylhexanoic acid;
(S)-2-(6-methoxy-2-pyrazinylamino)-5,5-dimethylhexanoic acid;
(S)-2-(5-methoxy-2-pyrazinylamino)-5,5-dimethylhexanoic acid;
(S)-2-[4-(benzyloxy)-2-pyrimidinylamino]-5,5-dimethylhexanoic acid;
(S)-5,5-dimethyl-2-(6-phenoxy-4-pyrimidinylamino)hexanoic acid;
(S)-2-(2,6-dimethoxy-4-pyrimidinylamino)-5,5-dimethylhexanoic acid;
(S)-5,5-Dimethyl-2-((2-methylquinazolin-4-yl)amino)hexanoic acid;
(S)-2-((2-Cyclopropylquinazolin-4-yl)amino)-5,5-dimethylhexanoic acid;
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof,
preferably wherein the compound is:
(S)-2-anilino-5,5-dimethylhexanoic acid;
(S)-5,5-dimethyl-2-(2-pyridylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(4-pyridylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(2-pyrazinylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(2-pyrimidinylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(5-pyrimidinylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(4-pyrimidinylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(4-quinazolinylamino)hexanoic acid;
(S)-5,5-dimethyl-2-(1,3,5-triaza-4-naphthylamino)hexanoic acid;
(S)-2-[5-(benzyloxy)-2-pyrimidinylamino]-5,5-dimethylhexanoic acid(S)
(S)-2-(5-methoxy-2-pyrimidinylamino)-5,5-dimethylhexanoic acid(S)
(S)-2-(4-methoxy-2-pyrimidinylamino)-5,5-dimethylhexanoic acid(S)
(S)-5,5-dimethyl-2-(4-morpholino-2-pyrimidinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(2-quinoxalinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(5-methyl-2-pyrazinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(3-methyl-2-pyrazinylamino)hexanoic acid(S)
(S)-2-(2-methoxy-4-pyrimidinylamino)-5,5-dimethylhexanoic acid(S)
(S)-2-(6-methoxy-4-pyrimidinylamino)-5,5-dimethylhexanoic acid(S)
(S)-5,5-dimethyl-2-(2-methyl-4-pyrimidinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(6-methyl-4-pyrimidinylamino)hexanoic acid(S)
(S)-2-(2,6-dimethyl-4-pyrimidinylamino)-5,5-dimethylhexanoic acid(S)
(S)-5,5-dimethyl-2-(8-methyl-4-quinazolinylamino)hexanoic acid
(S)-5,5-dimethyl-2-(6-methyl-2-pyrazinylamino)hexanoic acid(S)
(S)-5,5-dimethyl-2-(6-phenoxy-2-pyrazinylamino)hexanoic acid(S)
(S)-2-(4-isoquinolylamino)-5,5-dimethylhexanoic acid(S)
(S)-2-(m-chlorophenylamino)-5,5-dimethylhexanoic acid(S)
(S)-5,5-dimethyl-2-(3-pyridylamino)hexanoic acid
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-isoquinolylamine
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-3-quinolylamine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-2-quinolylamine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-1-naphthylamine;
N-phenyl[4-methyl-1-(2H-tetraazol-5-yl)pentyl]amine;
N-2-pyridyl[4-methyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl]-1-naphthylamine;
N-phenyl[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-2-quinolylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-2-pyrazinylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-3-isoquinolylamine;
N-phenyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]-3-quinolylamine;
N-2-pyrimidinyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-4-isoquinolylamine;
N-2-pyrimidinyl[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]-4-isoquinolylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-5-pyrimidinylamine;
N-5-pyrimidinyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
N-2-pyrazinyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl](1-methyl-1H-1,7-diazainden-5-yl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](1-methyl-1H-1,7-diazainden-5-yl)amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]-2-quinolylamine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl]-3-quinolylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-3-quinolylamine;
N-2-pyrimidinyl[4-methyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl]-2-quinolylamine;
N-3-pyridyl[4-methyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]-3-isoquinolylamine;
N-2-pyridyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
N-3-pyridyl[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]amine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-3-pyridylamine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl]-4-isoquinolylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-2-pyrimidinylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-2-pyridylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]aniline;
N-2-pyridyl[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
N-3-pyridyl[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](6-fluoro-4-quinazolinyl)amine;
[(R)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](6-fluoro-4-quinazolinyl)amine;
[(S)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](6-fluoro-4-quinazolinyl)amine;
[3,3-dimethyl-1-(2H-tetraazol-5-yl)butyl]-4-quinazolinylamine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](6-methoxy-4-quinazolinyl)amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl](6-methoxy-4-quinazolinyl)amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl](6-methyl-4-quinazolinyl)amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl](6-fluoro-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](7-fluoro-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](6-methyl-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](7-methyl-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](7-methoxy-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl][6-(trifluoromethyl)-4-quinazolinyl]amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl][7-(trifluoromethyl)-4-quinazolinyl]amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-1,3,7-triaza-4-naphthylamine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](2-methyl-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](7-bromo-4-quinazolinyl)amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl](7-methoxy-4-quinazolinyl)amine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl](2-phenyl-4-quinazolinyl)amine;
[(S)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-isoquinolylamine;
[(R)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-isoquinolylamine;
[(R)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-2-quinolylamine;
[(S)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-2-quinolylamine;
[(S)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-quinazolinylamine;
[(R)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-quinazolinylamine;
N-3-pyridyl[(S)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
N-3-pyridyl[(R)-4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]amine;
[4-methyl-1-(2H-tetraazol-5-yl)pentyl]-4-quinazolinylamine;
[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentyl]-4-quinazolinylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-4-quinazolinylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-4-pyridylamine;
[3-methyl-1-(2H-tetraazol-5-yl)butyl]-4-pyrimidinylamine;
4-[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentylamino]-7-quinazolinecarbonitrile;
4-[4,4-dimethyl-1-(2H-tetraazol-5-yl)pentylamino]-6-quinazolinecarbonitrile;
(S)-5,5-dimethyl-2-(o-phenoxyphenylamino)hexanoic acid;
(S)-2-anilino-4,4-dimethylvaleric acid;
(S)-2-anilino-2,5,5-trimethylhexanoic acid;
(S)-5,5-dimethyl-2-(4-phenyl-2-pyrimidinylamino)hexanoic acid;
(S)-2-[6-(benzyloxy)-2-pyrazinylamino]-5,5-dimethylhexanoic acid;
(S)-2-(6-methoxy-2-pyrazinylamino)-5,5-dimethylhexanoic acid;
(S)-2-(5-methoxy-2-pyrazinylamino)-5,5-dimethylhexanoic acid;
(S)-2-[4-(benzyloxy)-2-pyrimidinylamino]-5,5-dimethylhexanoic acid;
(S)-5,5-dimethyl-2-(6-phenoxy-4-pyrimidinylamino)hexanoic acid;
(S)-2-(2,6-dimethoxy-4-pyrimidinylamino)-5,5-dimethylhexanoic acid;
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof.

220 more elements

Dependencies are inferred from the claim text.

Facts

Application

19/162,794Filed 7 Mar 2024

Priority

EP 23160615.37 Mar 2023

Published

24 Sep 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification40 codes

C07C 229/18
Having only one amino and one carboxyl group bound to the carbon skeleton: the nitrogen atom of the amino group being further bound to carbon…
A61K 31/198
The amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine,…:…
A61K 31/41
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with two or more ring hetero atoms, at least…
A61K 31/437
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring…

Abstract

Facts

Application

19/162,794Filed 7 Mar 2024

Priority

EP 23160615.37 Mar 2023

Published

24 Sep 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification40 codes

C07C 229/18
Having only one amino and one carboxyl group bound to the carbon skeleton: the nitrogen atom of the amino group being further bound to carbon…
A61K 31/198
The amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine,…:…
A61K 31/41
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with two or more ring hetero atoms, at least…
A61K 31/437
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring…

Modulators of sortilin activity

Life of this patent

Abstract

Claims15

Modulators of sortilin activity

Life of this patent

Abstract

Claims15